Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent : a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Buccheri, Sergio ; Sarno, Giovanna ; Erlinge, David LU
; Renlund, Henrik
; Lagerqvist, Bo
; Grimfjärd, Per
; Witt, Nils
; Yndigegn, Troels
LU
; Fröbert, Ole
and Persson, Jonas
, et al.
(2021)
In EuroIntervention
16(17).
p.1413-1421
- Abstract
Aims: The aim of this study was to assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) (Orsiro) in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI). Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the two-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer-generation DES (n-DES group) were analysed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI]: 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% vs 2.0% with Orsiro... (More)
Aims: The aim of this study was to assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) (Orsiro) in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI). Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the two-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer-generation DES (n-DES group) were analysed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI]: 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% vs 2.0% with Orsiro and n-DES, adjusted HR 0.81, 95% CI: 0.63-1.03, p-value=0.09). The risk of target lesion revascularisation by PCI was lower in the Orsiro group (1.6% vs 2.3%, adjusted HR 0.75, 95% CI: 0.60-0.94, p-value=0.013). All-cause mortality and myocardial infarction did not show a statistically significant difference between the two groups (mortality of 7.5% in both groups, adjusted HR 0.99, 95% CI: 0.72-1.35, p-value=0.94; 6.0% vs 5.2% for myocardial infarction, adjusted HR 1.19, 95% CI: 1.00-1.43, p-value=0.06). Conclusions: In a nationwide scenario, the use of a sirolimus-eluting ultrathin-strut DES portended favourable clinical outcomes.
(Less)
- author
- Buccheri, Sergio
; Sarno, Giovanna
; Erlinge, David
LU
; Renlund, Henrik
; Lagerqvist, Bo
; Grimfjärd, Per
; Witt, Nils
; Yndigegn, Troels
LU
; Fröbert, Ole
and Persson, Jonas
, et al. (More)
- Buccheri, Sergio
; Sarno, Giovanna
; Erlinge, David
LU
; Renlund, Henrik
; Lagerqvist, Bo
; Grimfjärd, Per
; Witt, Nils
; Yndigegn, Troels
LU
; Fröbert, Ole
; Persson, Jonas
; Böhm, Felix
and James, Stefan
(Less)
- organization
- publishing date
- 2021-04-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- EuroIntervention
- volume
- 16
- issue
- 17
- pages
- 9 pages
- publisher
- Société Europa Edition
- external identifiers
-
- scopus:85105691466
- pmid:33016880
- ISSN
- 1774-024X
- DOI
- 10.4244/EIJ-D-20-00429
- language
- English
- LU publication?
- yes
- id
- 8d334e1e-caec-4971-b7e9-4edaff3d089b
- date added to LUP
- 2021-06-01 11:51:52
- date last changed
- 2024-12-15 07:45:04
@article{8d334e1e-caec-4971-b7e9-4edaff3d089b,
abstract = {{<p>Aims: The aim of this study was to assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) (Orsiro) in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI). Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the two-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer-generation DES (n-DES group) were analysed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI]: 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% vs 2.0% with Orsiro and n-DES, adjusted HR 0.81, 95% CI: 0.63-1.03, p-value=0.09). The risk of target lesion revascularisation by PCI was lower in the Orsiro group (1.6% vs 2.3%, adjusted HR 0.75, 95% CI: 0.60-0.94, p-value=0.013). All-cause mortality and myocardial infarction did not show a statistically significant difference between the two groups (mortality of 7.5% in both groups, adjusted HR 0.99, 95% CI: 0.72-1.35, p-value=0.94; 6.0% vs 5.2% for myocardial infarction, adjusted HR 1.19, 95% CI: 1.00-1.43, p-value=0.06). Conclusions: In a nationwide scenario, the use of a sirolimus-eluting ultrathin-strut DES portended favourable clinical outcomes.</p>}},
author = {{Buccheri, Sergio and Sarno, Giovanna and Erlinge, David and Renlund, Henrik and Lagerqvist, Bo and Grimfjärd, Per and Witt, Nils and Yndigegn, Troels and Fröbert, Ole and Persson, Jonas and Böhm, Felix and James, Stefan}},
issn = {{1774-024X}},
language = {{eng}},
month = {{04}},
number = {{17}},
pages = {{1413--1421}},
publisher = {{Société Europa Edition}},
series = {{EuroIntervention}},
title = {{Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent : a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)}},
url = {{http://dx.doi.org/10.4244/EIJ-D-20-00429}},
doi = {{10.4244/EIJ-D-20-00429}},
volume = {{16}},
year = {{2021}},
}